

Financial news for PLX dated on 2020-06-08: 10 Biggest Price Target Changes For Monday

Financial news for PLX dated on 2020-06-08: HC Wainwright & Co. Maintains Buy on Protalix BioTherapeutics, Raises Price Target to \$11

Financial news for PLX dated on 2020-06-01: Protalix BioTherapeutics shares are trading higher after the company reported better-than-expected Q1 EPS and sales results.

Financial news for PLX dated on 2020-06-01: Protalix BioTherapeutics Q1 EPS \$0.10 Beats \$(0.30) Estimate, Sales \$21.65M Beat \$6.60M Estimate

Financial news for PLX dated on 2020-06-01: Earnings Scheduled For June 1, 2020

Financial news for PLX dated on 2020-05-30: The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight

Financial news for PLX dated on 2020-05-28: Protalix BioTherapeutics Reports Submission Of Biologics License Application For Pegunigalsidase Alfa For Treatment Of Fabry Disease

Financial news for PLX dated on 2020-05-11: 32 Stocks Moving in Monday's Pre-Market Session

Financial news for PLX dated on 2020-05-11: Protalix BioTherapeutics Announces Positive Topline Results from the BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

Financial news for PLX dated on 2020-05-04: 98 Biggest Movers From Friday

Financial news for PLX dated on 2020-05-01: 58 Stocks Moving In Friday's Mid-Day Session

Financial news for PLX dated on 2020-05-01: 72 Biggest Movers From Yesterday

Financial news for PLX dated on 2020-04-30: 61 Stocks Moving In Thursday's Mid-Day Session

Financial news for PLX dated on 2020-04-15: 78 Biggest Movers From Yesterday

Financial news for PLX dated on 2020-04-14: 55 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PLX dated on 2020-04-14: 86 Biggest Movers From Yesterday

Financial news for PLX dated on 2020-03-30: Protalix 13G Filing From Alrov Properties/Technorov/Alfred Akirov Shows 9.99% Stake In Co.

Financial news for PLX dated on 2020-03-16: Protalix Biotherapeutics Announces Feasibility Study with Kirin Holdings on the Production of a Novel Complex Protein

Financial news for PLX dated on 2020-03-12: 90 Stocks Moving In Thursday's Mid-Day Session

Financial news for PLX dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for PLX dated on 2020-03-08: The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Financial news for PLX dated on 2020-03-02: 140 Biggest Movers From Friday

Financial news for PLX dated on 2020-02-28: 86 Stocks Moving In Friday's Mid-Day Session

Financial news for PLX dated on 2020-02-28: 46 Stocks Moving in Friday's Pre-Market Session

Financial news for PLX dated on 2020-02-10: Protalix BioTherapeutics Presents Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease

Financial news for PLX dated on 2020-02-10: 30 Stocks Moving in Monday's Pre-Market Session

Financial news for PLX dated on 2020-02-06: Protalix Reports Receipt Of Agreement Letter With Chiesi Farma For Initial Pediatric Study Plan For PRX-102 For Treatment Of Fabry Disease

Financial news for PLX dated on 2020-02-03: 30 Stocks Moving in Monday's Pre-Market Session

Financial news for PLX dated on 2020-02-03: 82 Biggest Movers From Friday

Financial news for PLX dated on 2020-01-22: 26 Stocks Moving in Wednesday's Pre-Market Session

Financial news for PLX dated on 2020-01-22: 82 Biggest Movers From Yesterday

Financial news for PLX dated on 2020-01-15: 80 Biggest Movers From Yesterday

Financial news for PLX dated on 2020-01-14: 48 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PLX dated on 2020-01-09: 54 Biggest Movers From Yesterday

Financial news for PLX dated on 2020-01-08: 40 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PLX dated on 2020-01-08: 27 Stocks Moving in Wednesday's Pre-Market Session

Financial news for PLX dated on 2020-01-07: 50 Biggest Movers From Yesterday

Financial news for PLX dated on 2020-01-06: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for PLX dated on 2020-01-06: 24 Stocks Moving in Monday's Pre-Market Session

Financial news for PLX dated on 2020-01-02: 63 Biggest Movers From Tuesday

Financial news for PLX dated on 2019-12-31: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PLX dated on 2019-12-30: 58 Biggest Movers From Friday

Financial news for PLX dated on 2019-12-27: 46 Stocks Moving In Friday's Mid-Day Session

Financial news for PLX dated on 2019-12-09: Protalix BioTherapeutics Reports 1-For-10 Reverse Stock Split, Effective Dec. 19, 2019

Financial news for PLX dated on 2019-11-19: Protalix BioTherapeutics shares are trading lower as a potential sell-off after the stock increased roughly 68% yesterday.

Financial news for PLX dated on 2019-11-18: Protalix BioTherapeutics and Chiesi Farmaceutici Announce Successful pre-BLA Meeting with FDA for Accelerated Approval of Pegunigalsidase

Financial news for PLX dated on 2019-11-07: Protalix BioTherapeutics Q3 EPS \$(0.02) Beats \$(0.03) Estimate, Sales \$14.248M Beat \$11.6M Estimate

Financial news for PLX dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for PLX dated on 2019-10-17: Protalix BioTherapeutics Announces Positive 12-Month Interim Data From BRIDGE Phase III Open Label Switch-Over Study Showing Pegunigalsidase Alfa For The Treatment Of Fabry Disease Was Well Tolerated

Financial news for PLX dated on 2019-09-24: Protalix BioTherapeutics And Chiesi Group Complete Enrollment In Third Phase III Clinical Trial Of pegunigalsidase Alfa (PRX-102) For Treatment Of Fabry Disease

Financial news for PLX dated on 2019-09-04: The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Financial news for PLX dated on 2019-08-30: Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

Financial news for PLX dated on 2019-08-29: The Daily Biotech Pulse: EC Approves Roche's Tecentriq For Breast Cancer, Trevena On Track For NDA Resubmission, Edap Earnings

Financial news for PLX dated on 2019-08-22: Protalix BioTherapeutics Evaluating And Pursuing Alternatives

Financial news for PLX dated on 2019-08-09: 110 Biggest Movers From Yesterday

Financial news for PLX dated on 2019-08-08: 90 Stocks Moving In Thursday's Mid-Day Session

Financial news for PLX dated on 2019-08-08: Protalix BioTherapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Financial news for PLX dated on 2019-08-08: The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

Financial news for PLX dated on 2019-08-08: Protalix BioTherapeutics Q2 EPS \$(0.05) Misses \$(0.03) Estimate, Sales \$12.247M Beat \$11.75M Estimate

Financial news for PLX dated on 2019-07-29: Protalix BioTherapeutics Announces Eyal Rubin CFO

Financial news for PLX dated on 2019-06-17: Protalix BioTherapeutics Completes Enrollment in the Phase III BRIGHT Clinical Trial of pegunigalsidase alfa (PRX 102) for the Treatment of Fabry Disease

Financial news for PLX dated on 2019-06-06: Protalix BioTherapeutics, Chiesi Report Will Apply For Accelerated Approval Of Pegunigalsidase Alfa For Treatment Of Fabry Disease In US

Financial news for PLX dated on 2019-05-21: Protalix Names Dror Bashan Pres, CEO

Financial news for PLX dated on 2019-03-29: Protalix BioTherapeutics S-3 Shows Registration For \$100M Mixed Securities Offering

Financial news for PLX dated on 2019-03-18: Protalix BioTherapeutics Says it Will Restate its Q1, Q2 and Q3 2018 Financials to Recognize Revenue Which Was Not Previously Recognized

Financial news for PLX dated on 2019-03-18: Earnings Scheduled For March 18, 2019

Financial news for PLX dated on 2019-02-07: The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut

Financial news for PLX dated on 2019-02-05: Protalix BioTherapeutics Highlights Prelim. Data From BRIGHT Study Of pegunigalsidase alfa for the Treatment of Fabry Disease Will Be Featured at the 15th Annual WORLDSymposium

Financial news for PLX dated on 2019-02-03: The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Financial news for PLX dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for PLX dated on 2018-12-17: Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease

Financial news for PLX dated on 2018-11-07: Protalix BioTherapeutics Q3 EPS \$(0.10) Misses \$(0.04) Estimate, Sales \$663K Miss \$7.98M Estimate

Financial news for PLX dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for PLX dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for PLX dated on 2018-10-05: The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker

Financial news for PLX dated on 2018-10-05: Protalix To Highlight Prelim. Data From BRIDGE Study Of Pegunigalsidase Alfa For Treatment Of Fabry Disease At 1st Canadian Symposium on Lysosomal Diseases

Financial news for PLX dated on 2018-09-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for PLX dated on 2018-09-21: Protalix Shares Open For Trade, Now Up 16% At \$0.74/Share

Financial news for PLX dated on 2018-09-21: Protalix BioTherapeutics Shares Halted, News Pending

Financial news for PLX dated on 2018-07-25: 46 Biggest Movers From Yesterday

Financial news for PLX dated on 2018-07-24: Mid-Afternoon Market Update: NASDAQ Turns Negative; Whirlpool Shares Drop After Earnings Miss

Financial news for PLX dated on 2018-07-24: 34 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PLX dated on 2018-07-24: Mid-Day Market Update: Crude Oil Up Over 1%; Protalix BioTherapeutics Shares Spike Higher

Financial news for PLX dated on 2018-07-24: Benzinga Pro's 5 Stocks To Watch Today

Financial news for PLX dated on 2018-07-24: Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102; Co. To Receive \$25M Up Front, \$20M In Development Costs, And \$760M In Potential Milestones

Financial news for PLX dated on 2018-06-05: Protalix BioTherapeutics Announces Additional Positive Results From Final Analysis Of The Phase II Clinical Trial Of OPRX-106 For Treatment Of Ulcerative Colitis

Financial news for PLX dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for PLX dated on 2018-05-25: UPDATE: Protalix Says 'Remaining Effective Enzyme in Blood Samples was more than Double for Pegunigalsidase Alfa (PRX-102) Compared to Fabrazyme(r) as a Result of Higher Inhibition of Neutralizing Antibodies Measured in Fabrazyme'

Financial news for PLX dated on 2018-05-25: Protalix BioTherapeutics Reports Poster Presentation On Baseline Characteristics For Fabry Disease Patients Screened In Phase II BALANCE Study Of Pegunigalsidase Alfa

Financial news for PLX dated on 2018-05-09: Protalix BioTherapeutics Q1 EPS \$(0.06) Beats \$(0.09) Estimate, Sales \$4.553M Beat \$4.4M Estimate

Financial news for PLX dated on 2018-03-13: Benzinga Pro's 5 Stock To Watch Today

Financial news for PLX dated on 2018-03-13: Protalix BioTherapeutics' Phase 2 Trial of OPRX-106 for the Treatment of Ulcerative Colitis Meets Efficacy Endpoints

Financial news for PLX dated on 2018-03-06: Protalix BioTherapeutics Reports FY EPS \$(0.65) vs \$(0.29) Est., Sales \$19.24M vs \$27.76M Est.

Financial news for PLX dated on 2018-01-31: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PLX dated on 2018-01-31: Protalix BioTherapeutics' Pegunigalsidase Receives Fast Track Designation From the FDA

Financial news for PLX dated on 2018-01-31: Protalix Reports Pegunigalsidase Alfa Received Fast Track Designation

Financial news for PLX dated on 2018-01-03: 35 Biggest Movers From Yesterday

Financial news for PLX dated on 2018-01-02: 28 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PLX dated on 2018-01-02: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PLX dated on 2018-01-02: Protalix BioTherapeutics Reports 'Positive' Interim Data from Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis

Financial news for PLX dated on 2017-12-27: 25 Stocks Moving In Wednesday's Mid-Day Session

Financial news for PLX dated on 2017-12-27: 22 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PLX dated on 2017-12-27: A Peek Into The Markets: U.S. Stock Futures Mostly Flat Ahead Of Consumer Confidence, Pending Home Sales Data

Financial news for PLX dated on 2017-12-27: Protalix BioTherapeutics' PRX-102 Granted Orphan Drug Designation by the European Commission

Financial news for PLX dated on 2017-11-29: Protalix BioTherapeutics Completes

Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis

Financial news for PLX dated on 2017-11-27: Protalix BioTherapeutics Presents 'Positive' Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference

Financial news for PLX dated on 2017-11-13: 28 Stocks Moving In Monday's Mid-Day Session

Financial news for PLX dated on 2017-11-13: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for PLX dated on 2017-11-13: Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 From COMP and EMA

Financial news for PLX dated on 2017-10-18: Protalix BioTherapeutics +38.46% Premarket @\$0.90 After Co Reports Exclusive Ex-US Partnership With Chiesi Farmaceutici For Development, Commercialization Of PRX-102 For Treatment Of Fabry Disease

Financial news for PLX dated on 2017-10-18: UPDATE: Protalix Will Receive \$25M Upfront, Added \$25M In Development Costs, Added Up To \$320M In Potential Regulatory, Commercial Milestone Payments

Financial news for PLX dated on 2017-10-18: UPDATE: Protalix Grants Chiesi Ex-US Rights To PRX-102

Financial news for PLX dated on 2017-10-18: Protalix BioTherapeutics Reports Entered Into Exclusive Ex-US Partnership With Chiesi Farmaceutici For Development, Commercialization Of PRX-102 For Treatment Of Fabry Disease

Financial news for PLX dated on 2017-06-07: Protalix Offers Phase II Trial Results for Alidornase Alfa in CF: Showed 'meaningful decrease in efficacy parameters once treatment with alidornase alfa stopped further supporting alidornase alfa clinical efficacy'

Financial news for PLX dated on 2017-06-01: Protalix Reports FDA Approval for Operation of Current Facility as Multi-Product Facility

Financial news for PLX dated on 2017-05-10: Protalix BioTherapeutics Reports Q1 EPS \$(0.48) vs \$(0.09) in Same Qtr. Last Year, Sales \$2.889M vs \$2.55M Est.

Financial news for PLX dated on 2017-05-09: Protalix Reports FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa

Financial news for PLX dated on 2017-04-18: Protalix BioTherapeutics Reports Preclinical Results Showing Positive Effect of PRX-102 on Small-Fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies

Financial news for PLX dated on 2017-04-17: 7 Biggest Price Target Changes For Monday

Financial news for PLX dated on 2017-04-17: Rodman & Renshaw Reiterates Buy On Protalix BioTherapeutics, Raises Price Target To \$5

Financial news for PLX dated on 2017-04-12: 10 Biggest Mid-Day Losers For Wednesday

Financial news for PLX dated on 2017-04-12: Adam Feuerstein Tweets: \$PLX Cystic Fibrosis Drug Study Results Worsen Over Time --> thestreet.com/story/14083744...

Financial news for PLX dated on 2017-04-12: Protalix Offers Results from Phase II Trial of AIR DNase for Treatment of Cystic Fibrosis: Show 'Number of Clinically Relevant Parameters Suggest Improved Lung Function'

Financial news for PLX dated on 2017-03-16: Protalix Reports FY16 EPS \$(0.29) vs \$0.61 in FY15, Sales \$9.199M

Financial news for PLX dated on 2017-02-13: 18 Biggest Mid-Day Gainers For Monday

Financial news for PLX dated on 2017-01-09: Protalix Bio Therapeutics Gives 2017 Objectives

Financial news for PLX dated on 2017-01-03: 15 Biggest Mid-Day Losers For Tuesday

Financial news for PLX dated on 2017-01-03: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PLX dated on 2017-01-03: Protalix BioTherapeutics Reports Positive Results from Phase II Clinical Trial of alidornase alfa

Financial news for PLX dated on 2016-12-27: Protalix Receives Confirmation Of \$24M Order of alfataliglycerase To Treat Brazilian Patients With Gaucher

Financial news for PLX dated on 2016-12-22: Protalix BioTherapeutics Enrolls Last Patient in AIR DNase Phase 2 Trial

Financial news for PLX dated on 2016-12-14: Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately \$24 Million of alfataliglycerase By Brazilian Ministry Of Health to Treat Gaucher Patients in Brazil

Financial news for PLX dated on 2016-12-09: European Crohn's, Colitis Organisation Issues New Statement Support a Switch to Biosimilar from Reference Product in Inflammatory Bowel Disease

Financial news for PLX dated on 2016-11-30: Protalix BioTherapeutics Enrolls First Patient in Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

Financial news for PLX dated on 2016-11-09: Protalix BioTherapeutics Reports Q3 EPS \$(0.07) vs \$(0.10) Est., Sales \$7.118M vs \$4.364M in Same Qtr. Last Year

Financial news for PLX dated on 2016-09-07: Protalix Reports Results from Phase I/II Trial of PRX-102 for Treatment of Fabry Disease at SSIEM; Co. Recruiting Patients for Phase III Pivotal Trial

Financial news for PLX dated on 2016-08-10: UPDATE: Protalix Biotherapeutics Says PRX-102 Was Well Tolerated; Majority of Adverse Events were Mild, Moderate

Financial news for PLX dated on 2016-08-10: UPDATE: Protalix Reports Added Data from Phase I/II Trial for PRX-102 for Treatment of Fabry Disease: Improvements of Stabilization in Efficacy Were Demonstrated Across All Disease Parameters

Financial news for PLX dated on 2016-08-10: Protalix BioTherapeutics Releases Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease

Financial news for PLX dated on 2016-08-08: Protalix Reports Q2 EPS \$(0.11) vs \$(0.08) Est., Sales \$1.769M vs \$1M Est.

Financial news for PLX dated on 2016-07-07: Protalix BioTherapeutics Reports First Patient Dosed in the AIR DNase Phase II Clinical Trial for Cystic Fibrosis

Financial news for PLX dated on 2016-06-06: Protalix BioTherapeutics Starts PRX-102 Global Phase III Clinical Trial of Fabry Disease to Support United States and European Filings

Financial news for PLX dated on 2016-06-06: Protalix BioTherapeutics Initiates PRX-102 Phase III Study

Financial news for PLX dated on 2016-05-09: Protalix Bio Therapeutics Q1 EPS (\$0.09) vs (\$0.08) est, Revenue \$679K vs \$1.1M est

Financial news for PLX dated on 2016-04-04: Benzinga's Top Initiations

Financial news for PLX dated on 2016-04-04: Rodman & Renshaw Initiates Coverage on Protalix BioTherapeutics at Buy, Announces \$3.50 PT

Financial news for PLX dated on 2016-03-08: Protalix BioTherapeutics Reports FY15 EPS \$0.61 vs. Est. \$0.68

Financial news for PLX dated on 2016-03-03: Protalix BioTherapeutics Presents Positive Six and Twelve Month Interim Clinical Data on PRX-102 for the Treatment of Fabry Disease at the 12th Annual WORLDSymposium(tm) 2016

Financial news for PLX dated on 2015-11-09: Protalix BioTherapeutics Reports Q3 EPS \$(0.04) vs. Est. \$(0.08), Rev. \$4.3M vs. Est. \$5M

Financial news for PLX dated on 2015-10-19: Protalix BioTherapeutics Reports Positive Long Term Data on PRX-102 for Fabry Disease

Financial news for PLX dated on 2015-10-13: Morning Market Gainers

Financial news for PLX dated on 2015-10-13: Protalix BioTherapeutics Sells Share In ELELYSO Partnership & 6% Stake In Protalix To Pfizer For \$46M

Financial news for PLX dated on 2015-10-05: Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF

Financial news for PLX dated on 2015-09-09: US Stock Futures Point To Higher Open

Financial news for PLX dated on 2015-09-09: Protalix BioTherapeutics Announces Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease

Financial news for PLX dated on 2015-09-09: Protalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease

Financial news for PLX dated on 2015-08-10: Protalix Reports Q2 Net Loss of \$0.05/Share, Sales \$3.8M

Financial news for PLX dated on 2015-08-03: Protalix Reports Phase I Clinical Study Results for PRX-106 Showed Favorable Safety, Tolerability Profile Activity

Financial news for PLX dated on 2015-06-12: Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference

Financial news for PLX dated on 2015-05-07: Protalix Reports Q1 Loss of \$0.06/Share vs Loss of \$0.08/Share Est., Sales \$4.4M vs \$8.2M Est.

Financial news for PLX dated on 2015-05-07: Protalix Biotherapeutics Reports Q1 EPS \$0.06 Vs Est Loss \$0.08, May Not Compare, Revs \$4.39M Vs Est \$8.20M

Financial news for PLX dated on 2015-04-23: Jefferies Initiates Coverage on Protalix BioTherapeutics at Buy, Announces \$2.60 PT

Financial news for PLX dated on 2015-03-12: Protalix BioTherapeutics Reports FY14 EPS \$(0.30) vs. Est \$(0.27), Rev. \$10.5M vs. Est. \$31.09M

Financial news for PLX dated on 2015-02-12: Protalix BioTherapeutics Presents Positive Phase I/II Interim Clinical Data on PRX-102 for Fabry Disease at WORLD Symposium

Financial news for PLX dated on 2015-02-02: Protalix BioTherapeutics Completes Enrollment in Phase I/II Clinical Trial of PRX-102 for Fabry Disease

Financial news for PLX dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

Financial news for PLX dated on 2015-01-08: Pharmaceuticals, Therapeutics And A Retailer On The Move Thursday Morning

Financial news for PLX dated on 2015-01-08: Protanx Announces Positive Interim Efficacy For PRX-102 Trial

Financial news for PLX dated on 2015-01-05: Protalix Unveils New Strategy for Accelerated Growth: Expecting to Initiate Phase III Trial for PRX 102 in Early '16

Financial news for PLX dated on 2014-10-13: Protalix Biotherapeutics Shares Move Higher; Mention as IBIO Sympathy Play

Financial news for PLX dated on 2014-09-29: Protalix BioTherapeutics Names Moshe Manor as President and CEO

Financial news for PLX dated on 2014-08-28: UPDATE: Protalix Shares Spike Higher on FDA Approval of Pediatric Indication for ELELYSO(TM) for Injection, for IV Use for Treatment of Type 1 Gaucher Disease

Financial news for PLX dated on 2014-08-28: Protalix Shares Spike Higher on FDA Approval of Pediatric Indication for ELELYSO(TM) for Injection, for IV Use for Treatment of Type 1 Gaucher Disease

Financial news for PLX dated on 2014-08-28: Amended 13D Filing from Bio-Cell on Protalix Shows Deal to Seek Buyers for 4.4M Shares, Will Sell Shares at \$2.47/Share

Financial news for PLX dated on 2014-08-24: 3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology

Financial news for PLX dated on 2014-08-07: Protalix Biotherapeutics Reports Q2 Loss of \$0.07/Share vs \$0.07/Share Loss Est.

Financial news for PLX dated on 2014-07-01: Stocks Hitting 52-Week Lows

Financial news for PLX dated on 2014-06-23: Protalix Biotherapeutics Reports New Data on ELELYSO, Oral GCD Will Be Presented at European Working Group on Gaucher Disease

Financial news for PLX dated on 2014-06-18: Protalix Initiates Phase II PRX-112 Study

Financial news for PLX dated on 2014-05-30: Protalix Announces ELELYSO Approved in

Canada

Financial news for PLX dated on 2014-05-22: Protalix Reports ELELYSO Approved in Australia for Treatment of Gaucher Disease in Adults, Pediatric Patients

Financial news for PLX dated on 2014-05-22: Protalix Announces Elelyso Approved in Austrailia

Financial news for PLX dated on 2014-05-08: Protective Life Corporation Reports Q1 Revenue of \$6.70M vs \$1.06B Est

Financial news for PLX dated on 2014-04-23: Protalix Announces Data on Oral antiTNF to be Presented at Digestive Disease Week 2014 Meeting

Financial news for PLX dated on 2014-03-13: Protalix BioTherapeutics, Inc. Reports Q4 EPS of \$(0.12) vs \$(0.03) Est

Financial news for PLX dated on 2014-02-12: Protalix Biotherapeutics Announces Oral GCD Data Will Be Presented at WORLD Symposium 2014

Financial news for PLX dated on 2014-01-24: RF Lafferty & Co. Initiates Coverage on Protalix BioTherapeutics, Inc. at Buy

Financial news for PLX dated on 2014-01-23: Protalix Offers Update on Health Canada Evaluation, Says Manufacturing Facility Utilizing ProCelleX Deemed Acceptable by EMA, FDA, IMH, ANVISA, TGA

Financial news for PLX dated on 2013-10-21: JP Morgan Initiates Coverage on Protalix BioTherapeutics, Inc. at Overweight, Announces \$7.00 PT

Financial news for PLX dated on 2013-10-14: Protalix Reports Oral GCD Well Tolerated, Active Enzyme Detected in Blood

Financial news for PLX dated on 2013-09-18: Protalix Reports Closing of \$69M Offering of Convertible Notes, Will Receive \$66.8M in Net Proceeds from Offering

Financial news for PLX dated on 2013-09-11: Protalix BioTherapeutics Announces Proposed \$60M Offering of Convertible Notes

Financial news for PLX dated on 2013-05-14: (OPTIONS): Protalix June \$5.00 Puts Trade 2,500 Times Over 120 OI, August \$5.00 Puts Trade 2,000 Times Over 99 OI

Financial news for PLX dated on 2013-04-29: (OPTIONS): Protalix November OTM 5.00 Puts Trade 2,000 Times Over an OI of 3

Financial news for PLX dated on 2013-04-29: Protalix Says COFEPRIS, Public Health Institute of Chile Grant Approval to UPLYSO for Type 1 Gaucher Disease

Financial news for PLX dated on 2013-04-02: Protalix Expects Phase 1 Trial of PRX112 Complete in Q3

Financial news for PLX dated on 2013-03-18: UPDATE: Pfizer, Protalix Receive ANVISA Approval for UPLYSO in Brazil

Financial news for PLX dated on 2013-03-18: Pfizer, Protalix Says Brazil Approvs Uplyso

Financial news for PLX dated on 2013-02-13: Protalix Says New Clinical Data on ELELYSO Will Be Presented at WORLD Symposium

Financial news for PLX dated on 2013-02-05: Benzinga's M&A Chatter for Tuesday February 5, 2013

Financial news for PLX dated on 2013-02-05: Mid-Afternoon Market Update: Markets Edge Toward Record Highs, Arch Coal Falls Further

Financial news for PLX dated on 2013-02-05: Mid-Day Market Update: Markets Rally Further, Clean Harbors Drops on CFO Controversy

Financial news for PLX dated on 2013-02-05: Protalix Says Reviewing Partnering, Other Alternatives

Financial news for PLX dated on 2013-02-05: Protalix Exploring Strategic Review

Financial news for PLX dated on 2013-02-05: Protalix Spokesperson Declines Comment on Pfizer Headline

Financial news for PLX dated on 2013-02-05: Calcalist Reporting Pfizer Said to Have Expressed Interest in Protalix, Co. Could Be Valued at Around \$1B

Financial news for PLX dated on 2012-12-06: Protalix BioTherapeutics Signs Clinical Development Agreement With Pfizer for ELELYSO

Financial news for PLX dated on 2012-12-06: Protalix Signs Clinical Development Pact for Elelyso with Pfizer

Financial news for PLX dated on 2012-11-09: UPDATE: Jefferies & Company Reiterates Hold Rating, Lowers PT on Protalix BioTherapeutics

Financial news for PLX dated on 2012-11-09: Jefferies & Company Maintains Protalix BioTherapeutics at Hold, Lowers PT from \$6 to \$5.50

Financial news for PLX dated on 2012-08-13: Protalix BioTherapeutics Receives FDA IND Clearance to Initiate a Phase I/II Study of Fabry Disease Patients With PRX-102

Financial news for PLX dated on 2012-07-16: UPDATE: Aegis Capital Reiterates Hold Rating, Lowers PT on Protalix BioTherapeutics

Financial news for PLX dated on 2012-07-16: Aegis Capital Maintains Protalix BioTherapeutics at Hold, Lowers PT from \$7 to \$5.50

Financial news for PLX dated on 2012-07-02: Protalix BioTherapeutics Announces New Clinical Data on taliglucerase alfa Presented at the 10th Annual European Working Group on Gaucher Disease Meeting

Financial news for PLX dated on 2012-06-25: Benzinga's Downgrade Summary for June 25, 2012

Financial news for PLX dated on 2012-06-25: UPDATE: Wells Fargo Downgrades Protalix BioTherapeutics to Market Peform on EU Challenges for Elelyso

Financial news for PLX dated on 2012-06-25: Wells Fargo Downgrades Protalix BioTherapeutics from Outperform to Market Perform

Financial news for PLX dated on 2012-06-22: EMA Adopts Opinion on Taliglucerase Alfa Marketing Authorization Application

Financial news for PLX dated on 2012-06-11: Protalix Receives a \$25 Million Milestone Payment for U.S. Approval of ELELYSO

Financial news for PLX dated on 2012-05-02: Option Alert: Protalix Biotherapeutics Put Volume at 1,146% of Average

Financial news for PLX dated on 2012-05-02: Protalix BioTherapeutics Spiking Lower on Heavy Volume; Currently at \$7.24

Financial news for PLX dated on 2012-05-02: Protalix BioTherapeutics Rises 29% Pre-Market on FDA Approval for Elelyso

Financial news for PLX dated on 2012-05-01: FDA Approves Protalix, Pfizer Drug To Treat Gaucher Disease

Financial news for PLX dated on 2012-05-01: Protalix BioTherapeutics Gets FDA Approval for Elelyso

Financial news for PLX dated on 2012-03-19: Protalix Biotherapeutics Spikig Lower on Heavy Volume

Financial news for PLX dated on 2012-02-22: Protalix Biotherapeutics Sold 5.18M Shares at \$5.25 per Share; Will Use Shares to Fund Trials and Research

Financial news for PLX dated on 2012-02-17: Notable Call Options Activity in Protalix BioTherapeutics

Financial news for PLX dated on 2012-02-16: Protalix BioTherapeutics Announces the Pricing of Public Offering of Common Stock

Financial news for PLX dated on 2012-02-15: Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock; No Amount Given

Financial news for PLX dated on 2011-12-06: FDA Delays Protalix's Drug Decision; Investors Feel Sick

Financial news for PLX dated on 2011-12-06: Morning Market Losers

Financial news for PLX dated on 2011-12-06: FDA Extends Taliglucerase Alfa PDUFA Date to May 1, 2012

Financial news for PLX dated on 2011-11-22: Pluristem Therapeutics' CEO Letter to Shareholders: "Current Data Suggest that Approx 20% of CLI patients will Die Within the first 6-12 Months"

Financial news for PLX dated on 2011-11-10: Protalix's Acetylcholinesterase Demonstrates Potential Role in the Treatment of Parkinson's Disease

Financial news for PLX dated on 2011-09-16: Pluristem Therapeutics CEO Letter to Shareholders

Financial news for PLX dated on 2011-09-08: Protalix BioTherapeutics' Taliglucerase Alfa Phase III Results Published in Blood, the Journal of the American Society of Hematology

Financial news for PLX dated on 2011-08-17: Protalix BioTherapeutics Announces FDA Accepts for Review Complete Response Resubmission for Taliglucerase Alfa and Assigns PDUFA Date

Financial news for PLX dated on 2011-08-01: Protalix Submits Reply to FDA Complete Response Letter for Taliglucerase Alfa and Reports Top-Line Results from the Company's Switchover Trial

Financial news for PLX dated on 2011-07-21: Protalix To File Drug Approval Request To FDA within Days -Globes

Financial news for PLX dated on 2011-06-01: Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer

Financial news for PLX dated on 2011-06-01: Hapoalim Cutting Ocverage On Multitude Of Names

Financial news for PLX dated on 2011-05-05: Biotech/ Biodefense Sector Trading Alert

Financial news for PLX dated on 2011-04-08: Biotech/ Biodefense Sector Trading Alert

Financial news for PLX dated on 2011-03-17: Protalix BioTherapeutics Announces Proposed Public Offering of Common Stock

Financial news for PLX dated on 2011-02-25: Protalix BioTherapeutics Trading Significantly Lower Today (PLX)

Financial news for PLX dated on 2011-02-25: FDA Issues Complete Response Letter for Taliglucerase Alfa New Drug Application

Financial news for PLX dated on 2011-01-20: Pfizer Inks Deal With Theraclone - Analyst Blog

Financial news for PLX dated on 2011-01-20: Pfizer Inks Deal With Theraclone - Analyst Blog

Financial news for PLX dated on 2010-12-10: Wells Fargo Initiates Coverage On PLX With An Outperform Rating And A Valuation Range Of \$12-14

Financial news for PLX dated on 2010-12-09: Canadian Approval for Shire Drug - Analyst Blog

Financial news for PLX dated on 2010-12-09: Canadian Approval for Shire Drug - Analyst Blog

Financial news for PLX dated on 2010-11-29: Pfizer/Protalix Seek EU Approval - Analyst Blog

Financial news for PLX dated on 2010-11-29: Pfizer/Protalix Seek EU Approval - Analyst Blog

Financial news for PLX dated on 2010-10-14: UBS Reiterates Coverage On (VFC, SBUX, PLX, KED, HAIN, GEL, KO, AFL, CSX)

Financial news for PLX dated on 2010-09-08: Protalix BioTherapeutics And PROLOR Biotech May Rise On "Protein Acquisition" (PBTH, PLX)

Financial news for PLX dated on 2010-08-31: Genzyme Rejects Sanofi Offer - Analyst Blog

Financial news for PLX dated on 2010-08-27: European Approval for Shire Drug - Analyst Blog

Financial news for PLX dated on 2010-08-25: Protalix BioTherapeutics Up Strong This Morning (PLX)

Financial news for PLX dated on 2010-01-13: Benzinga's News Roundup (MGA, ASML, PCS, PLX, MRNA, ROSG)

Financial news for PLX dated on 2009-12-01: Benzinga's News Roundup (SPLS, PFE, LINE, ED, STT)

Financial news for PLX dated on 2009-11-02: New 52-Week High Stocks (RCKY, TTEC, UFS, PRGO, PLX)